Sailong Pharmaceutical Group's subsidiary has obtained the registration certificate for aspartate potassium magnesium injection.
*ST Sealon (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sealon Pharmaceutical (Changsha) Co., Ltd., recently obtained the "Drug Registration Certificate" issued by the National Medical Products Administration for aspartate potassium magnesium injection. Aspartate potassium magnesium injection is mainly used for the treatment of hypokalemia, ventricular arrhythmias caused by digitalis poisoning, as well as the adjuvant treatment of myocarditis sequelae, congestive heart failure, and myocardial infarction.
Sailong Pharmaceutical Group (002898.SZ) announced that its fully-owned subsidiary, Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., recently obtained the "Drug Registration Certificate" for Potassium Magnesium Aspartate Injection issued by the National Medical Products Administration. Potassium Magnesium Aspartate Injection is mainly used for the treatment of hypokalemia, ventricular arrhythmias caused by digitalis poisoning, post-myocarditis sequelae, congestive heart failure, and as an adjunctive therapy for myocardial infarction.
Related Articles
Sinomedia (00623) repurchased 428,000 shares for HK$834,600 on June 16.
CHINA TOWER (00788): Yin Wenkai appointed as executive director.
Bank of China (03988) will distribute the third round of dividends for domestic preference shares on June 29th.
Sinomedia (00623) repurchased 428,000 shares for HK$834,600 on June 16.
CHINA TOWER (00788): Yin Wenkai appointed as executive director.
Bank of China (03988) will distribute the third round of dividends for domestic preference shares on June 29th.
RECOMMEND
